Trial · NCT02014116
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of LY3009120 | Part A LY3009120 | 300 | milligrams (mg) | ||
| Number of Participants With Tumor Response | Cohort A | Complete Repsonse | 0 | participants | |
| Number of Participants With Tumor Response | Cohort B | Complete Repsonse | 0 | participants | |
| Number of Participants With Tumor Response | Cohort C | Complete Repsonse | 0 | participants | |
| Number of Participants With Tumor Response | Cohort A | Partial Response | 0 | participants | |
| Number of Participants With Tumor Response | Cohort B | Partial Response | 0 | participants | |
| Number of Participants With Tumor Response | Cohort C | Partial Response | 0 | participants | |
| Number of Participants With Tumor Response | Cohort A | Stable Disease | 0 | participants | |
| Number of Participants With Tumor Response | Cohort B | Stable Disease | 0 | participants | |
| Number of Participants With Tumor Response | Cohort C | Stable Disease | 5 | participants | |
| Number of Participants With Tumor Response | Cohort A | Progressive Disease | 1 | participants | |
| Number of Participants With Tumor Response | Cohort B | Progressive Disease | 4 | participants | |
| Number of Participants With Tumor Response | Cohort C | Progressive Disease | 1 | participants | |
| Number of Participants With Tumor Response | Cohort A | Not Assessed | 0 | participants | |
| Number of Participants With Tumor Response | Cohort B | Not Assessed | 1 | participants | |
| Number of Participants With Tumor Response | Cohort C | Not Assessed | 4 | participants | |
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120 Cycle 1 Day 1 | 50 mg LY3009120 | 105.29 | Geometric Coefficient of Variation 228.24 | nanogram per milliliter (ng/mL) | |
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120 Cycle 1 Day 1 | 100 mg LY3009120 | 436 | Geometric Coefficient of Variation 96 | nanogram per milliliter (ng/mL) | |
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120 Cycle 1 Day 1 | 200 mg LY3009120 | 675 | Geometric Coefficient of Variation 81 | nanogram per milliliter (ng/mL) | |
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120 Cycle 1 Day 1 | 300 mg LY3009120 | 976 | Geometric Coefficient of Variation 72 | nanogram per milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02014116/results